**Appendix 6.4 Other solutions**

***(The other solutions are as below. The device does not contain any European Pharmacopoeia.***

|  |  |  |
| --- | --- | --- |
| ***SN*** | ***Solution*** | ***Title*** |
| ***1*** | ***Regulation(EU) 2017/745.*** | ***Medical devices regulations*** |
| ***2*** | ***MEDDEV 2.12/1 rev 8***  ***(January 2013)+(July 2019)*** | ***Guidelines on a medical devices vigilance system＋***  ***[Additional guidance on MEDDEV 2.12/1 rev.8](https://ec.europa.eu/docsroom/documents/36292)*** |
| ***3*** | ***MEDDEV 2.7.1 Rev.4***  ***(June 2016)*** | ***Guidelines On Medical Devices-Clinical evaluation: A Guide for manufacturers and notified bodies*** |
| ***4*** | ***MEDDEV 2.12/2 rev. 2***  ***(January 2012)*** | ***Guidelines on medical devices:Post market clinical follow-up studies - A guide for manufacturers and notified bodies*** |
| ***5*** | ***[MDCG 2020-7](https://ec.europa.eu/health/sites/health/files/md_sector/docs/md_mdcg_2020_7_guidance_pmcf_plan_template_en.pdf)*** | ***Post-marhet clinical follow-up (PMCF) plan template - A guide for manufacturers and notified bodies*** |
| ***6*** | ***MDCG 2020-5*** | ***A guide for manufacturers and notified bodies: Clinical Evaluation - Equivalence*** |
| ***7*** | ***MDCG 2020-13*** | ***Clinical evaluation assessment report template*** |
| ***\*\*\**** | ***\*\*\*\**** | ***\*\*\*\**** |

***)***